58394-99-3Relevant academic research and scientific papers
From Zn(II) to Cu(II) framework via single-crystal to single-crystal metathesis with superior gas uptake and heterogeneous catalytic properties
Gupta, Mayank,De, Dinesh,Tomar, Kapil,Bharadwaj, Parimal K.
, p. 925 - 934 (2018)
In this work, a Zn(II) framework, {[Zn2(L)4(H2O)4]·(7DMF)(7H2O)}n (1Zn), has been synthesized using a bent tetracarboxylic acid ligand (H4L). The structure of 1Zn contains [Zn2(COO)4] paddle-wheel secondary building units with axial sites occupied by water molecules. Interestingly, the isostructural Cu(II) framework {[Cu2(L)4(H2O)4]·(7DMF)(7H2O)}n (1Cu) has been obtained via single-crystal to single-crystal metathesis reaction. The activated 1Cu (denoted as a1Cu; a stands for activated) has open coordination sites. This species showed enhanced CO2 adsorption and heterogeneous catalytic properties for the Hantzsch coupling reaction involving condensation of an aldehyde with ethyl acetoacetate and ammonium acetate to produce 1,4-dihydropyridines, and three-component coupling of amines, aldehydes and alkynes to generate propargylic amines with high efficiency.
COMPOUNDS AND COMBINATIONS THEREOF FOR INHIBITING BETA-AMYLOID PRODUCTION AND METHODS OF USE THEREOF
-
Page/Page column 146-147, (2010/11/29)
Provided are compounds which can be used in combination for treating diseases associated with a condition associated with cerebral accumulation of Alzheimer’s amyloid, such as Alzheimer’s disease. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer’s amyloid by administering therapeutically effective amounts of compounds which in combination can decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer’s amyloid in animals or humans by administering diagnostically effective amounts of the compounds.
